In last trading session, Evaxion Biotech A/S ADR (NASDAQ:EVAX) saw 0.22 million shares changing hands with its beta currently measuring -0.23. Company’s recent per share price level of $0.89 trading at -$0.03 or -2.73% at ring of the bell on the day assigns it a market valuation of $4.81M. That closing price of EVAX’s stock is at a discount of -1429.21% from its 52-week high price of $13.61 and is indicating a premium of 6.74% from its 52-week low price of $0.83. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.83 million shares which gives us an average trading volume of 340.04K if we extend that period to 3-months.
For Evaxion Biotech A/S ADR (EVAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Evaxion Biotech A/S ADR (NASDAQ:EVAX) trade information
Upright in the red during last session for losing -2.73%, in the last five days EVAX remained trading in the green while hitting it’s week-highest on Monday, 01/06/25 when the stock touched $0.89 price level, adding 10.1% to its value on the day. Evaxion Biotech A/S ADR’s shares saw a change of 5.28% in year-to-date performance and have moved 5.28% in past 5-day. Evaxion Biotech A/S ADR (NASDAQ:EVAX) showed a performance of -33.58% in past 30-days. Number of shares sold short was 0.12 million shares which calculate 1.64 days to cover the short interests.
Evaxion Biotech A/S ADR (EVAX) estimates and forecasts
Statistics highlight that Evaxion Biotech A/S ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -72.02% of value to its shares in past 6 months, showing an annual growth rate of 81.48% while that of industry is 17.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -18.88% during past 5 years.
